Inbar Finkel
Tel Aviv, TA, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Prognostic Stratification of Brain Metastases from Nonanaplastic Follicular Cell-Derived Thyroid Carcinoma: Results of an International Multicenter Retrospective Study.
Journal: Thyroid : official journal of the American Thyroid Association
Published: August 03, 2026
Response-adapted surgical de-escalation following neoadjuvant immunotherapy in resectable mucosal HNSCC A systematic review and meta-analysis.
Journal: Oral oncology
Published: May 09, 2026
Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer.
Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer.
Journal: European thyroid journal
Published: December 12, 2025
BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer.
Journal: Archives of endocrinology and metabolism
Published: October 31, 2025
BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.
Journal: Frontiers in endocrinology
Published: August 28, 2025
Does previous neck dissection or irradiation mitigate the response to immunotherapy in advanced/metastatic head and neck squamous cell carcinoma?
Journal: International journal of oral and maxillofacial surgery
Published: July 15, 2025
Risk of Contralateral Central Compartment Recurrence Following Unilateral Therapeutic Neck Dissection for Papillary Thyroid Carcinoma.
Journal: Journal of surgical oncology
Published: May 24, 2025
In reply to: "Letter to the editor in response to the article:'Squamous cell carcinoma arising in chronically damaged skin (Marjolijn's Ulcer)'".
Journal: The oncologist
Published: April 19, 2025
Squamous cell carcinoma arising in chronically damaged skin (Marjolin's Ulcer): still an unmet need in the era of immunotherapy.
Journal: The oncologist
Published: June 14, 2024
First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
Journal: Frontiers in oncology
Published: December 06, 2022
Last Updated: 09/26/2026